Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235390 | 0.87 | PLA2G2A (0.55) | PLA2G2APLA2G4BALDH1A1TP53TSHR | |
| SCHEMBL89628 | 0.85 | KDM4E (0.50) | PLA2G2AFFAR4HCAR3KDM4EALDH1A1 | |
| SCHEMBL20749484 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL3216400 | 0.81 | TAS1R3 (0.39) | PLA2G2AFFAR4HCAR3KDM4EALDH1A1 | |
| SCHEMBL88767 | 0.79 | ALDH1A1 (0.33) | KDM4EALDH1A1MAPTTSHRMEN1 | |
| SCHEMBL89635 | 0.78 | CBFB (0.33) | KDM4EALDH1A1MAPTTSHRMEN1 | |
| SCHEMBL8235386 | 0.77 | ALDH1A1 (0.45) | PLA2G2AHCAR3KDM4EALDH1A1MAPT | |
| SCHEMBL1424790 | 0.76 | ALOX15 (0.48) | PLA2G2AKDM4EALDH1A1MAPTTP53 | |
| SCHEMBL13490849 | 0.75 | KDM4C (0.49) | PLA2G4BHCAR3KDM4EALDH1A1MAPT | |
| SCHEMBL15087930 | 0.75 | MEN1 (0.30) | ALDH1A1MAPTTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | PLA2G2A 3728/4885FFAR4 3058/4885PLA2G4B 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.